17.58

3.69% 0.6276

Novocure Ltd (NVCR)

Overview News Price History Option Chain Financials Why NVCR Down? Discussions Forecast

Novocure Ltd stock is traded at $17.58, with a volume of 542.66K. It is up +3.69% in the last 24 hours and up +10.40% over the past month. NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Previous Close:

$16.95

Open:

$16.78

24h Volume:

542.66K

Relative Volume:

0.34

Market Cap:

$2.05B

Revenue:

$674.41M

Net Income/Loss:

$-173.05M

P/E Ratio:

-11.46

EPS:

-1.5343

Net Cash Flow:

$-48.07M

1W Performance:

+1.53%

1M Performance:

+10.40%

6M Performance:

+57.91%

1Y Performance:

+49.83%

1-Day Range:

$16.78

$17.76

1-Week Range:

$16.78

$17.83

52-Week Range:

$9.82

$21.45

Novocure Ltd Stock (NVCR) Company Profile

Name

Novocure Ltd

Sector

Healthcare (1089)

Industry

Medical Devices (141)

Phone

44 (0)15 3475 6700

Address

NO. 4 THE FORUM, ST. HELIER

Employee

1,605

Twitter

@novocure

Next Earnings Date

2026-07-23

Latest SEC Filings

NVCR's Discussions on Twitter

Compare NVCR vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NVCR Novocure Ltd	17.58	1.97B	674.41M	-173.05M	-48.07M	-1.5343
ABT Abbott Laboratories	109.87	192.51B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	331.93	130.11B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	90.60	116.83B	36.36B	4.84B	5.43B	3.7261
BSX Boston Scientific Corp	51.44	75.11B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	90.77	52.80B	6.30B	1.07B	1.09B	1.8406

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Jul-08-25	Initiated	Ladenburg Thalmann	Buy
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight
Aug-04-23	Initiated	SVB Securities	Outperform
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-05-23	Reiterated	H.C. Wainwright	Buy
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy
Feb-08-22	Initiated	Loop Capital	Buy
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-20-22	Upgrade	Truist	Hold → Buy
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform
Jan-25-21	Reiterated	Piper Sandler	Overweight
Sep-23-20	Initiated	Northland Capital	Outperform
Sep-18-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-17-20	Downgrade	Truist	Buy → Hold
Jun-01-20	Resumed	Oppenheimer	Perform
May-01-20	Downgrade	Oppenheimer	Outperform → Perform
Apr-09-20	Downgrade	Evercore ISI	In-line → Underperform
Mar-05-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-19	Upgrade	SunTrust	Hold → Buy
Jul-26-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-26-19	Downgrade	Wedbush	Outperform → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Nov-02-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-16-18	Initiated	Evercore ISI	Outperform
Apr-18-18	Reiterated	Mizuho	Buy
Feb-23-18	Reiterated	Mizuho	Buy
May-24-17	Upgrade	Wells Fargo	Market Perform → Outperform
Jul-29-16	Reiterated	Wedbush	Outperform
Jan-19-16	Initiated	Barclays	Underweight
Dec-02-15	Initiated	Deutsche Bank	Hold

View All

Novocure Ltd Stock (NVCR) Latest News

Aug 14, 2026

NVCR|Novocure Ltd|Price:16.950|Chg%:-0.430 - TradingKey

Aug 14, 2026

Aug 12, 2026

Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet - Yahoo Finance

Aug 12, 2026

NovoCure (NVCR) Is Up 8.5% After Advancing Tumor Treating Fields Pipeline And Trials ProgressHas The Bull Case Changed? - simplywall.st

Aug 12, 2026

Aug 11, 2026

First Trust Advisors LP Invests $1.03 Million in NovoCure Limited $NVCR - marketbeat.com

Aug 11, 2026

NovoCure (NVDA) Following TTFields Optimism And FDA Approval Hopes Looks Undervalued - Sahm

Aug 11, 2026

Aug 08, 2026

NovoCure (NASDAQ:NVCR) Rating Increased to Buy at Wall Street Zen - marketbeat.com

Aug 08, 2026

Aug 07, 2026